Part, Chapter, Paragraph
1 I, 3. 1 | fertility is below the so-called replacement level of 2.2 children per
2 I, 3. 1 | decline to (well) below the replacement level; currently, these
3 I, 3. 1 | EU, although still below replacement; Southern and Eastern European
4 I, 3. 1 | number of children below replacement. Women from birth cohort
5 I, 3. 1 | reproductive life) finished below replacement fertility in all countries
6 I, 3. 1 | completed fertility below replacement. On average, women born
7 II, 5. 4. 1| failure (necessitating renal replacement therapy: dialysis or transplantation);~
8 II, 5. 4. 2| or transplantation (renal replacement therapy in patients with
9 II, 5. 4. 2| dialysis/transplantation (renal replacement therapy) in patients with
10 II, 5. 4. 2| or transplantation (renal replacement therapy) per 100,000 individuals
11 II, 5. 6.Acr| Adjusted Life Years~HRT~Hormone Replacement Therapy~NSAIDs~Non-steroidal
12 II, 5. 6. 3| menopause is unclear but hormone replacement therapy (HRT) is associated
13 II, 5. 6. 3| and rehabilitation. Joint replacement is a major cost. Total hip
14 II, 5. 6. 3| a major cost. Total hip replacement rates, usually for OA, vary
15 II, 5. 6. 3| estimated requirement for knee replacement is 27.4 joints per 1000
16 II, 5. 6. 3| may be controlled by joint replacement surgery although the costs
17 II, 5. 6. 3| pain management and joint replacement surgery.~ ~Although there
18 II, 5. 6. 3| repair of the fracture or replacement of the joint. At 1 year,
19 II, 5. 6. 6| Requirement for Primary Knee Replacement Surgery: a Cross-Sectional
20 II, 5. 6. 6| International Variation in Hip Replacement Rates. Ann Rheum Dis 62(
21 II, 5. 7.Acr| Outcomes Framework~RRT~Renal Replacement Therapy~WHO~World Health
22 II, 5. 7. 1| resulting cost of renal replacement treatments are still in
23 II, 5. 7. 1| al, 1997). Data on renal replacement therapy (RRT) for ESRD in
24 II, 5. 7. 1| most cost-effective renal replacement therapy (White et al, 2008).
25 II, 5. 7. 7| in the incidence of renal replacement therapy in developed countries
26 II, 5. 7. 7| and Financing for renal replacement therapy in Italy: an evolving
27 II, 5. 7. 7| in the incidence of renal replacement therapy for end-stage renal
28 II, 9 | if combined with hormone replacement therapy (Beral, 2003), and
29 II, 9. 3. 1| pathological changes requiring replacement therapy occur.~ ~While androgen
30 II, 9. 3. 1| for initiating Androgen Replacement Treatment (ART). In case
31 II, 9. 3. 1| if combined with hormone replacement therapy (Beral, 2003), and
32 II, 9. 3. 1| immunodeficiency syndrome~ART~Androgen Replacement Therapy~BMD~Bone Mineral
33 II, 9. 5. 3| if combined with hormone replacement therapy (Beral, 2003), and
34 III, 10. 2. 1| Non-communicable diseases~NRT~Nicotine replacement therpay~OECD~Organisation
35 III, 10. 2. 1| best results.~ ~Nicotine replacement therapy (NRT) in the form
36 III, 10. 2. 1| data suggest a possible replacement between stimulants, with
37 III, 10. 4. 2| sulfonate (PFBS) is used as replacement for PFOS, after the voluntary
38 IV, 11. 5. 5| growing demand of organ replacement therapy by increasing donation
39 IV, 11. 5. 6| quality indicators than other replacement therapies. Results of organ
40 IV, 12. 2 | yields best results. Nicotine replacement therapy (NRT) in form of
41 IV, 12. 10 | tobacco retailers~ ~ Nicotine Replacement Therapies made available
42 Key, Ap5. 0. 0| remediation~renal~renewable~replacement~reproductive~residential care~
